Navigation Links
PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
Date:3/7/2011

BOSTON, March 7, 2011 /PRNewswire/ -- Through various presentations to be delivered at the Drug Information Association (DIA) 23rd Annual EuroMeeting, being held March 28-30, 2011 in Geneva, Switzerland, experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address advanced approaches to help the biopharmaceutical industry meet demands of a changing global marketplace.

Experts from PAREXEL will be available at Stands 1050, 1052, 1151, and 1153 in the exhibit hall to discuss how the Company can help biopharmaceutical companies improve early-stage decisions, accelerate pivotal trials, reach new markets, and leverage technologies for increased operational quality and efficiency.  PAREXEL experts will discuss new operational models, supported by technology, to help its clients achieve greater benefits and speed development.

The DIA EuroMeeting program features the following presentations by PAREXEL experts, which address the benefits of combined clinical and technology expertise to enable more effective information flow and improved data access for greater visibility into trials – and ultimately, better decision making:

Tuesday, March 29

  • Session 1, 9:00: Use of Electronic Health Records for Clinical Research, Isabelle de Zegher, Worldwide Senior Director Technology Integration and Data Standards

  • Wednesday, March 30

  • Session 5, 9:00: How to Go Effectively from Data Collection in CDASH to Submission in SDTM: The need for an eCRF library, Isabelle de Zegher, Worldwide Senior Director Technology Integration & Data Standards
  • Session 6, 11:00: Using Technology to Improve the Clinical Trial Process, Liz Love, Product Manager
  • Session 8, 16:00: Simplicity (for sites) is the Ultimate Sophistication, Nikki Dowlman, Product Director

  • Poster Session:"Key Regulatory and Market Access Considerations: Gaining the Right Perspective for Regional and Global Development and Commercialization," which has a focus on the Asia/Pacific region, will provide insights to assist biopharmaceutical companies with strategic approaches to product development and commercialization, as well as to demonstrate product value to patients, payers, and providers, particularly in emerging high growth markets.

    Special Presentation:"Knowledge Management Enablers – Operational and Quality Control Centres," to be presented by Siegfried Schmitt, Ph.D., Principal Consultant, in Session 8 on Wednesday, March 30 at 16:00, will reinforce key Quality by Design (QbD) concepts. Dr. Schmitt will provide timely background and practical advice as regulators move forward on joint QbD pilot reviews and increase efforts toward regional harmonization.

    For more information about PAREXEL visit www.PAREXEL.com or Stands 1050, 1052, 1151, and 1153 during the meeting. Information about the 23rd Annual DIA EuroMeeting can be found at http://www.diahome.org.

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

    Kim Baker/Gene CarozzaPAREXEL International

    PAN CommunicationsTel: +781-434-4409

    Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com

    Email: PAREXEL@pancomm.com
    '/>"/>

    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
    2. PAREXEL Expands Global Clinical Pharmacology Capabilities
    3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
    4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
    5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
    6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
    7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
    8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
    9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
    10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
    11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
    (Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
    (Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Center for ... for caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. ... Seals Maine, will give parents and other caregivers the opportunity to share stories and ...
    (Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
    (Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
    (Date:12/2/2016)... ... 02, 2016 , ... More than half of American teens report losing their ... speaking with their child about sex related topics, less than 60 percent spoke about ... to announce the launch of its second edition of the “Sexual Wellness” campaign, aiming ...
    (Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
    Breaking Medicine News(10 mins):